OpenLB
Open Library of Bioscience
Advanced Search
Pathogens (Basel, Switzerland)
Feb 05, 2024;13 (2):

Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of .

Zhiwen Ma, Hong Xiao, Hailin Li, Xiaoling Lu, Jing Yan, Hao Nie, Qi Yin
Author Information
  1. Zhiwen Ma: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
  2. Hong Xiao: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
  3. Hailin Li: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
  4. Xiaoling Lu: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
  5. Jing Yan: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
  6. Hao Nie: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
  7. Qi Yin: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, No. 61 Daxuecheng Middle Road, Shapingba District, Chongqing 401334, China.
PMID: 38392883 DOI: 10.3390/pathogens13020145

Abstract

is known to generate bacterial biofilms that increase antibiotic resistance. With the increase of multi-drug resistance in recent years, the formulation of a new therapeutic strategy has seemed urgent. Preliminary findings show that Prodigiosin (PG), derived from chromium-resistant , exhibited efficient anti-biofilm activity against . However, its anti-biofilm activity against remains largely unexplored. The anti-biofilm activity of PG against three clinical single drug-resistant was evaluated using crystal violet staining, and the viability of biofilms and planktonic cells were also assessed. A model of chronic lung Infection was constructed to test the in vivo antibiofilm activity of PG. The results showed that PG inhibited biofilm formation and effectively inhibited the production of pyocyanin and extracellular polysaccharides in vitro, as well as moderated the expression of interleukins (IL-1��, IL-6, IL-10) and tumor necrosis factor (TNF-��) in vivo, which might be attributed to the downregulation of biofilm-related genes such as , , and . These findings suggest that PG could be a potential treatment for drug-resistant and chronic biofilm infections.

Keywords

Pseudomonas aeruginosa anti-biofilm chronic lung infection prodigiosin

References

  1. Antibiotics (Basel). 2021 Jul 25;10(8): [PMID: 34438957]
  2. Microorganisms. 2020 Sep 26;8(10): [PMID: 32993120]
  3. J Infect Public Health. 2020 Apr;13(4):598-605 [PMID: 31564530]
  4. Trends Microbiol. 2011 Aug;19(8):419-26 [PMID: 21664819]
  5. J Bacteriol. 2013 Apr;195(8):1623-6 [PMID: 23417492]
  6. J Virol. 2015 Aug;89(15):7449-56 [PMID: 25972556]
  7. Lancet Infect Dis. 2018 Mar;18(3):318-327 [PMID: 29276051]
  8. Microbiol Rev. 1996 Sep;60(3):539-74 [PMID: 8840786]
  9. Int Immunopharmacol. 2023 Mar;116:109800 [PMID: 36780827]
  10. Nat Prod Res. 2017 Mar;31(5):572-577 [PMID: 27353356]
  11. J Bacteriol. 2001 Sep;183(18):5395-401 [PMID: 11514525]
  12. J Mol Biol. 2015 Nov 20;427(23):3628-45 [PMID: 26319792]
  13. Int J Mol Sci. 2018 Nov 04;19(11): [PMID: 30400387]
  14. J Vis Exp. 2014 Mar 17;(85): [PMID: 24686327]
  15. Microbiologyopen. 2019 Dec;8(12):e933 [PMID: 31532581]
  16. Antimicrob Agents Chemother. 1993 Sep;37(9):1749-55 [PMID: 8239580]
  17. Biofouling. 2011 Aug;27(7):787-98 [PMID: 21797737]
  18. Curr Protein Pept Sci. 2020;21(3):313-323 [PMID: 31544690]
  19. Mar Biotechnol (NY). 2019 Feb;21(1):88-98 [PMID: 30612218]
  20. Bioorg Chem. 2023 Dec;141:106922 [PMID: 37865056]
  21. Biofouling. 2016 Nov;32(10):1171-1183 [PMID: 27739324]
  22. PLoS One. 2022 Feb 3;17(2):e0263522 [PMID: 35113972]
  23. Methods Mol Biol. 2014;1149:757-71 [PMID: 24818948]
  24. Appl Microbiol. 1969 Nov;18(5):936-7 [PMID: 4984207]
  25. J Bacteriol. 2004 Jul;186(14):4457-65 [PMID: 15231777]
  26. J Clin Invest. 2013 Jan;123(1):138-49 [PMID: 23241959]
  27. Diagn Microbiol Infect Dis. 2018 Apr;90(4):311-315 [PMID: 29310949]
  28. Biofouling. 2023 Mar-Apr;39(4):444-458 [PMID: 37369552]
  29. Drug Resist Updat. 2019 May;44:100640 [PMID: 31492517]
  30. Int J Mol Sci. 2021 Nov 29;22(23): [PMID: 34884697]
  31. Curr Pharm Biotechnol. 2002 Jun;3(2):77-98 [PMID: 12022261]
  32. Iran J Basic Med Sci. 2023;26(12):1475-1483 [PMID: 37970438]
  33. J Antimicrob Chemother. 2020 Nov 1;75(11):3248-3259 [PMID: 32737484]
  34. Front Microbiol. 2016 Jun 27;7:972 [PMID: 27446013]
  35. Mol Microbiol. 2004 Feb;51(3):675-90 [PMID: 14731271]
  36. Acta Biomater. 2018 Nov;81:93-102 [PMID: 30267885]
  37. J Bacteriol. 2001 Dec;183(23):6746-51 [PMID: 11698361]
  38. PLoS Pathog. 2009 Mar;5(3):e1000354 [PMID: 19325879]
  39. Biofouling. 2017 Jan;33(1):88-97 [PMID: 27936915]
  40. Toxicol Appl Pharmacol. 2011 Nov 15;257(1):137-47 [PMID: 21925195]
  41. Eur Rev Med Pharmacol Sci. 2022 Feb;26(4):1388-1397 [PMID: 35253195]
  42. Curr Res Microb Sci. 2022 Nov 17;3:100175 [PMID: 36518176]
  43. Ecotoxicol Environ Saf. 2021 Nov 22;228:112899 [PMID: 34823212]
  44. Int J Mol Sci. 2020 Nov 17;21(22): [PMID: 33212950]
  45. J Biosci Bioeng. 2006 Feb;101(2):157-61 [PMID: 16569612]
  46. Wound Repair Regen. 2008 Jan-Feb;16(1):2-10 [PMID: 18211573]
  47. Int J Mol Sci. 2019 Jul 12;20(14): [PMID: 31336824]
  48. PLoS Pathog. 2011 Jan 27;7(1):e1001264 [PMID: 21298031]
  49. Microb Pathog. 2022 Mar;164:105449 [PMID: 35183700]
  50. Int J Antimicrob Agents. 1999 May;11(3-4):217-21; discussion 237-9 [PMID: 10394973]

Grants

  1. No.32100139/National Natural Science Foundation of China
  2. No.sl202100000725/The Project of Chongqing Science and Technology Bureau

MeSH Term

Biofilms
Pseudomonas aeruginosa
Prodigiosin
Pseudomonas Infections
Anti-Bacterial Agents
Animals
Mice
Humans
Microbial Sensitivity Tests
Serratia marcescens

Chemicals

Prodigiosin
Anti-Bacterial Agents
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0PGanti-biofilmactivitychronicbiofilmsincreaseresistancefindingsProdigiosindrug-resistantlunginfectionvivoinhibitedbiofilmknowngeneratebacterialantibioticmulti-drugrecentyearsformulationnewtherapeuticstrategyseemedurgentPreliminaryshowderivedchromium-resistantexhibitedefficientHoweverremainslargelyunexploredthreeclinicalsingleevaluatedusingcrystalvioletstainingviabilityplanktoniccellsalsoassessedmodelconstructedtestantibiofilmresultsshowedformationeffectivelyproductionpyocyaninextracellularpolysaccharidesvitrowellmoderatedexpressioninterleukinsIL-1��IL-6IL-10tumornecrosisfactorTNF-��mightattributeddownregulationbiofilm-relatedgenessuggestpotentialtreatmentinfectionsAntibiofilmAgentBacterialBiofilm-AssociatedInfectionPseudomonasaeruginosaprodigiosin

Similar Articles

Cited By (3)